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Nanoparticulate CpG Immunotherapy in RAO-Affected Horses:
Phase I and IIa Study
J. Klier, B. Lehmann, S. Fuchs, S. Reese, A. Hirschmann, C. Coester, G. Winter, and H. Gehlen
Background: Recurrent airway obstruction (RAO), an asthma-like disease, is 1 of the most common allergic diseases in
horses in the northern hemisphere. Hypersensitivity reactions to environmental antigens cause an allergic inflammatory
response in the equine airways. Cytosine-phosphate-guanosine-oligodeoxynucleotides (CpG-ODN) are known to direct the
immune system toward a Th1-pathway, and away from the pro-allergic Th2-line (Th2/Th1-shift). Gelatin nanoparticles
(GNPs) are biocompatible and biodegradable immunological inert drug delivery systems that protect CpG-ODN against
nuclease degeneration. Preliminary studies on the inhalation of GNP-bound CpG-ODN in RAO-affected horses have shown
promising results.
Objectives: The aim of this study was to evaluate the clinical and immunological effects of GNP-bound CpG-ODN in a
double-blinded, placebo-controlled, prospective, randomized clinical trial and to verify a sustained effect post-treatment.
Animals and Methods: Twenty-four RAO-affected horses received 1 inhalation every 2 days for 5 consecutive administra-
tions. Horses were examined for clinical, endoscopic, cytological, and blood biochemical variables before the inhalation regi-
men (I), immediately afterwards (II), and 4 weeks post-treatment (III).
Results: At time points I and II, administration of treatment rather than placebo corresponded to a statistically significant
decrease in respiratory effort, nasal discharge, tracheal secretion, and viscosity, AaDO2 and neutrophil percentage, and an
increase in arterial oxygen pressure.
Conclusion and Clinical Importance: Administration of a GNP-bound CpG-ODN formulation caused a potent and persis-
tent effect on allergic and inflammatory-induced clinical variables in RAO-affected horses. This treatment, therefore, provides
an innovative, promising, and well-tolerated strategy beyond conventional symptomatic long-term therapy and could serve as
a model for asthma treatment in humans.
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Recurrent airway obstruction (RAO) is 1 of the mostcommon immune-mediated allergic conditions in
horses in the northern hemisphere.1–3 RAO could serve
as a natural model for allergic asthma in humans and
shares many characteristics with this disease.2,4 Trigger
factors are assumed to be allergens in dusty hay and
moldy straw (depending on the geographical location),
harmful gases (eg, ammonia, particulate matter from
the environment in the stable5) infectious diseases,1 and
genetic and epigenetic factors.6 The underlying patho-
genesis presumably is a hypersensitivity immune reac-
tion (types I, III, and IV) resulting in hyperreactivity of
the airways to these triggers.3,7,8 Clinical variables
include cholinergic bronchospasm, hypercrinia and dys-
crinia, nasal discharge, coughing, airway neutrophilia,
airway remodeling, and edema, resulting in poor perfor-
mance.1,8,9
Cytosine-phosphate-guanosine-oligodeoxynucleotide
(CpG-ODN) has been identified as a molecule that
directs the immune system toward a cell-mediated Th1
pathway, away from the pro-allergic humoral Th2 line
response, described as a Th2/Th1-shift.3,10,11 Unmethy-
lated CpG-ODN molecules exist naturally in prokary-
otic viral and bacterial DNA and stimulate the
mammalian immune system, via the Th1 pathway,
against infectious agents.10,11 A recognition receptor for
CpG-ODN is the toll-like-receptor-9 (TLR-9) which has
been identified in macrophages, bronchial epithelial
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AaDO2 arterio-alveolar oxygen pressure difference
BAL bronchoalveolar lavage
BALF bronchoalveolar lavage fluid
bpm breaths per minute
CpG-ODN cytosine-phosphate-guanosine-oligodeoxynucleotide
GNP gelatin nanoparticle
HPW highly purified water
IFN interferon
IL interleukin
PaO2 partial oxygen pressure




TLR-9 toll-like receptor 9
Tregs T regulatory cells
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cells, capillary endothelial cells, and neutrophil granulo-
cytes in equine lungs.12 Drug delivery systems such as
lipid13 or gelatin nanoparticles (GNPs) have been used
to protect CpG-ODN in vivo against nuclease degenera-
tion.14,15 GNPs represents a highly efficient drug deliv-
ery system, which also has the advantages of being
aerodynamically stable after inhalation, immunologi-
cally inert, biodegradable, and biocompatible.14–19
As an adjuvant, CpG-ODN has been successfully
used both in a human phase I and IIa in vivo asthma
study with the house dust mite allergen as well as in a
study of atopic dogs with specific allergens as an aller-
gen-specific immunotherapy.20,21 CpG-ODN also has
been applied as an adjuvant in in vitro and in vivo vac-
cination studies.22–25 Furthermore, it has been used as
an adjuvant in an equine influenza vaccine in horses23
and in combination with a Rhodococcus equi vaccine.22
A preliminary study of the inhalation of GNP-bound
CpG-ODN as the only active agent showed promising
clinical results in a small group of RAO-affected horses
and healthy horses, in contrast to previously used adju-
vants.26 No local or systemic inflammatory reactions
were observed.26 The efficiency of this novel formula-
tion was demonstrated by improvement in arterial
blood gases, breathing rate, amount of intratracheal
mucus accumulation, viscosity, and airway neutrophilia
in RAO-affected horses.26
The goal of this exploratory study was (i) to verify
the results of the previous pilot study using a larger
subject group and with a placebo control, and (ii) to
investigate a possible sustained response in the weeks
after treatment in the field. The main goals of the field
study were the evaluation of (i) a clinically relevant
improvement in breathing pattern, respiratory rate,
arterial blood gases, and AaDO2, as well as (ii) a clini-
cally relevant percentage decrease in neutrophilic granu-
locytes in the airways, as well as decrease in
intrapleural pressure, nasal discharge, amount of secre-
tion, and viscosity of secretions in the airways in com-
parison to the initial examination and the control group
after 5 inhalations of nanoparticle-bound CpG-ODN.
Additionally, the duration of the effectiveness of the
nanoparticle immunotherapy, as well as the tolerability
of the formulation and the absence of adverse effects,
were examined.
The first hypothesis of this study was that placebo
administration would show no or very limited improve-
ment in the monitored variables in comparison to the
experimental administration. The secondary hypothesis
was that the nanoparticle-bound CpG-ODN immuno-




This study was performed as a randomized, double-blinded, and
placebo-controlled clinical trial. The subjects were 24 horses with a
history of chronic RAO (mean age, 16.1 years  5.1; 5 mares, 17
geldings, and 2 stallions; mean weight, 519.4 kg  129.7). The
following inclusion criteria were applied: increased respiratory rate
at rest (>16/min), increased abdominal breathing(“heaves”), abnor-
mal auscultatory findings at rest, increased numbers of neutrophils
in the airways (>25%), decreased partial pressure of arterial oxygen
(<90 mmHg), increased intrapleural pressure (>15 cmH2O), and
clinical signs induced by contact with straw and hay, as well as
reversibility of clinical signs with avoidance of allergens and sus-
tained time on pasture1,27. All of the horses were kept in their usual
environment during the entire study (April through July) and were
examined without modifying their stabling (open bar stall, n = 7;
box with sawdust, n = 10; straw, n = 7), feeding (dry hay, n = 21;
soaked hay, n = 3) or activity. For at least 2 months before and
during the study, the horses received neither supplement medication
nor improvements to their stabling or management. This trial was
performed as an exploratory field study. In the placebo group, 25%
of the horses were kept in open stables and 75% in box stalls (bed-
ding material was shavings and sawdust in 38% and straw in 38%).
All of the horses in the placebo group were fed dry hay before and
during the study. In the active treatment group, 31% of the horses
were kept in open stables and 69% in stalls. In 81% of the cases, the
horses were fed dry hay and 19% were fed wet hay (only 3 of the
horses kept in stalls received wet hay).
Two different investigators performed the inhalation therapy
(BL) and clinical examinations (JK). In addition, the placebo and
experimental formulations could not be differentiated visually.
Neither the horse owners nor the examiners knew if the horse had
received the placebo or active treatment.
The patients were randomly assigned to 2 groups. After 8
horses were selected for the placebo group, the remaining horses
were assigned to the experimental treatment group. This randomi-
zation took place after all of the patients were selected for the
study. The placebo group (n = 8) received inhalations with highly
purified water (HPW) and GNP, and the experimental treatment
group (n = 16) received inhalations with GNP-bound CpG-ODN.a
,26 The inhalation regimen, corresponding to the procedure in the
previous study, was performed with the Equine Halerb and the
AeroNeb Go mesh vibrator.c ,26 In total, each horse received 5
inhalations, each separated by 2 days. The horses were examined 3
times: at the beginning, ie, before the first administration of exper-
imental treatment or placebo; (I) to determine each horsis clinical
status; directly after the final inhalation (II); and 4 weeks after the
final inhalation (III), to provide insight on the duration of effec-
tiveness. To this end, each examination included clinical examina-
tions, endoscopy, cytology, and serum biochemistry, as well as
measurement of intrapleural pressure.
The nanoparticles were produced and charged with CpG-ODN
according to the protocol of a previous study26. The study was
approved by the regional legal agency for animal testing of the
State Government of Bavaria, Germany (No. 55.2-1-54-2531-31-
10).
Clinical Examination and Scoring
The clinical variables were evaluated according to established
and standardized scoring systems when possible. The following
variables were examined: breathing rate per minute (bpm), breath-
ing type (relative units [RU] in the range of 0–3, where 0 = no or
little movement in the ventral flank and 3 = obvious abdominal
lift and heave line),28 nasal discharge (RU in the range of 0–2,
where 0 = none, 1 = mild and 2 = moderate discharge), ausculta-
tion of the lungs and trachea (in the range of RU 0 to 4, where
0 = physiological, 1 = mild, 2 = moderate, 3 = severe, 4 = wheeze
or rhonchus),1,26,27 and arterial blood gas parameters.29 The latter
consisted of partial oxygen pressure (paO2), with a normal refer-
ence value of 100  5 mmHg, and carbon dioxide pressure
(paCO2), with a normal reference value of 40  5 mmHg).
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Arterial blood gases were measured by an IRMA blood analysis
system.d The arterio-alveolar-oxygen-pressure difference (AaDO2)
was calculated from the actual air pressure and measured arterial
blood gases (AaDO2 = [actual air pressure  47 mmHg] 9
0.2095  PaCO2  PaO2).29 In addition, an endoscopic examina-
tion and a quantification of secretion (grade 0–5, where 0 = none,
clean, singular tracheobronchial secretion [TBS] to 5 = extreme,
profuse amounts)30 and viscosity (where grade 1 = fluid to 5 = vis-
cous)30 of the TBS was performed. Cytological examinations of
the TBS samples were performed to determine the percentage of
neutrophils in the total cell count after staining with Diff-Quick
solution.e Indirect measurement of the maximum intrapleural pres-
sure differences (D Ppl max) was performed by a Venti-Graphf via
esophageal probe.31
To test the tolerability of the formulation and its application,
the horses were regularly monitored for the signs of increased
nasal discharge, coughing, bronchospasm, increased respiratory
rate, endoscopically visible local hyperemia of the mucous mem-
branes, follicular hyperplasia, and decreased partial oxygen pres-
sure. Furthermore, body temperature, differential blood cell count,
and plasma fibrinogen concentration were measured to evaluate
the systemic effects of treatment.
Statistical Analysis
The comparison of patients within each group (placebo and
experimental treatment) for the preliminary examination before
treatment was carried out for normally distributed data (based on
Shapiro-Wilk analysis) with the paired Student’s t-test for para-
metric data. For non-parametric data, the Wilcoxon matched pairs
signed rank test was used for paired values (comparison within the
groups) and the Mann-Whitney test was used for unpaired data
(comparison between the groups). All statistical analyses were per-
formed using GraphPad Prism 5 software.g Results with a calcu-
lated value of P < 0.05 were considered statistically significant
(displayed as *; P < 0.01 as **; P < 0.001 as ***) and were
reported as the mean  S.D. The 95% confidence intervals (CI)
were calculated and presented in brackets. Effect size (Cohen‘s d)
was assessed for each piece of data (to estimate clinical relevance:
mild, d = 0.2–0.3; moderate, d = 0.5; large, d > 0.8). The




Throughout the whole study period, no local or sys-
temic inflammatory reactions or adverse effects were
observed after inhalation treatment with GNP-bound
CpG-ODN. Specifically, no clinically detectable
increased nasal discharge, coughing, bronchospasm,
increased breathing rate, endoscopically visible local
hyperemia, follicular hyperplasia, or decreased arterial
blood gas pressure were observed. In addition, no
increase in rectal temperature, peripheral blood absolute
and differential leukocyte counts or plasma fibrinogen
concentrations were detected.
Respiratory Rate
No clinically or statistically significant decrease in
respiratory rate was observed, either directly after pla-
cebo inhalation or after 4 weeks (Table 1, Fig 1). After
































































































































































































































































































































































































































































































































































































































































































































































































































































































































288 Klier et al
Fig 1. Relative reduction or increase of clinical, endoscopic, cytological, and biochemical parameters: Relative decrease or increase of
breathing rate and pattern (calculated value of P < 0.05 displayed as *; P < 0.01 as **; P < 0.001 as ***; P < 0.0001 as ****), lung auscul-
tation, intrapleural pressure measurement, oxygen partial pressure, AaDO2, percentage of neutrophils in TBS, nasal discharge, endoscopic
quantification of secretion and viscosity depicted in percent between first and second (I–II) and first and third (I–III) examinations and in
comparison between placebo (white bars, n = 8 RAO-affected horses) and treatment group (gray bars, n = 16 RAO-affected horses;
mean  SD).
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(P = 0.0856; clinical relevance, d = 0.6; CI:0.1 to 1.3)
could be detected immediately after treatment (Table 1,
Fig 1) or after 4 weeks (clinical relevance, d = 0.3; CI:
0.4 to 1.0). However, a statistically significant differ-
ence (P = 0.0247) in the percentage decrease in respira-
tory rate was detected between the placebo and
treatment groups between the first and last examination
(I–III) (Fig 1).
Breathing Pattern
The placebo group showed no statistically significant
improvement in breathing pattern after the inhalation
regimen (Table 1, Fig 1). However, a statistically signifi-
cant (P = 0.0007; d = 1.6; CI: 0.8–2.4) improvement in
breathing type was detected in the treatment group after
5 inhalations (Table 1, Fig 1), and a reduction of one
grade from the initial status was observed after 4 weeks
(P = 0.005; clinical relevance, d = 1.3; CI: 0.5–2.1)
(Table 1, Fig 1). A statistically significant difference was
detected between the placebo and experimental treat-
ment groups in percentage decrease in breathing pattern
between the first and second examination (I–II;
P = 0.0008) as well as between the first and third exam-
ination (I–III, P = 0.0051; Fig 1).
Lung Auscultation
No statistically significant improvement in ausculta-
tion was observed after the inhalation regimen in the
placebo group (Table 1, Fig 1). By contrast, a
significant (P = 0.0004; clinical relevance, d = 1.9; CI:
1.0–2.6) improvement in auscultation was detected in
the treatment group after 5 inhalations. In the treat-
ment group, a mean decrease of >1.5 grades was
observed. A significant decrease in duration of efficacy
(P = 0.0018; clinical relevance, d = 1.4; CI: 0.6–2.2)
also was observed in horses treated with GNP-bound
CpG after 4 weeks (Table 1, Fig 1). A statistically
significant difference was observed between the
placebo and treatment groups when comparing per-
centage improvement in auscultation between the first
and second examination (I–II; P < 0.0001) and
between the first and third examination (I–III;
P = 0.0015; Fig 1).
Intrapleural Pressure
No statistically significant decrease in intrapleural
pressure after inhalation treatment was observed in the
placebo group (Table 1, Fig 1). The treatment group
showed an average improvement in intrapleural pres-
sure of 16 cmH2O (clinical relevance, d = 1.0; CI: 0.2–
1.7) immediately after inhalation administration, but
this difference lacked statistical significance (P = 0.1269;
Table 1, Fig 1) because of large individual variations.
The clinical effect observed did not persist 4 weeks after
treatment. No statistically significant differences
between placebo and treatment group were observed
when comparing percentage intrapleural pressure
improvement (Fig 1).
Partial Oxygen Pressure (pO2)
The placebo group failed to show any statistically sig-
nificant improvement in arterial blood gas results post
inhalation (Table 1, Fig 1). However, pO2 increased on
average by approximately 14 mmHg in the treatment
group (from 71.4 mmHg  15.9 to 85.9 mmHg  13.1)
after 5 inhalations (P = 0.0006; clinical relevance,
d = 1.0; CI: 0.2–1.7) (Table 1). A persistent effect over
4 weeks was not observed in the treatment group
(P = 0.1523). A statistically significant difference was
observed between the placebo and treatment groups
when comparing the percentage increase of partial oxy-
gen pressure between the first and the second examina-
tion (I–II; P = 0.0228; Fig 1).
Arterio-alveolar Oxygen Pressure Difference
(AaDO2)
The placebo group showed an increase in AaDO2
after inhalation of HPW and GNP (Table 1, Fig 1). By
contrast, a decrease of 11 mmHg of AaDO2
(P = 0.0021; clinical relevance, d = 1.0; CI: 0.2–1.7) was
observed in the treatment group immediately after the
inhalation regime, with a statistically significant persis-
tent effect 4 weeks post-treatment (P = 0.022, clinical
relevance, d = 0.4; CI: 0.3 to 1.1; Table 1, Fig 1). A
statistically significant difference also was detected
between the placebo and treatment groups when com-
paring the percentage decrease of AaDO2 between the
first and the second examinations (I–II; P = 0.0174;
Fig 1).
Neutrophil Percentage
A statistically significant decrease in the neutrophil
percentage in TBS was not observed in the placebo
group (Table 1, Fig 1). After 4 weeks without treat-
ment, a mild increase in neutrophil percentage then was
detected in the placebo group (Table 1, Fig 1). How-
ever, in the treatment group, a statistically significant
decrease (P = 0.015, clinical relevance, d = 0.3; CI: 0.4
to 1.0) was observed after 5 inhalations (from
78.9  17.7% to 72.9  18.1%). Four weeks post-treat-
ment, no statistically significant effect (P = 0.0975, clini-
cal relevance, d = 0.4; CI: 0.3 to 1.1) was observed (to
70.2  24.4%) because of greater SD (Table 1, Fig 1).
No statistically significant difference between the pla-
cebo and treatment groups comparing the decrease of
neutrophil percentage was observed (I–II examination,
P = 0.1670; I–III examination, P = 0.0897; Fig 1).
Nasal Discharge
The placebo group showed no statistically significant
improvement in nasal discharge after the inhalation
regimen with HPW and GNP (Table 1, Fig 1). By con-
trast, within the treatment group, a statistically signifi-
cant decrease (P = 0.0012; clinical relevance, d = 1.5;
CI: 0.7–2.2) after 5 inhalations was observed (Table 1,
Fig 1). This effect persisted four weeks post-treatment
290 Klier et al
(P = 0.0048; clinical relevance, d = 1.3; CI: 0.5–2.0;
Table 1, Fig 1). A statistically significant difference was
detected between the placebo and experimental treat-
ment groups comparing the percentage decrease in nasal
discharge between the first and second examinations
(I–II; P = 0.0013) as well as between the first and third
examinations (I–III; P = 0.0135; Fig 1).
Quantity of Secretion
After the inhalation regimen with placebo, no statisti-
cally significant decrease in the amount of mucus was
observed on tracheal endoscopy (Table 1, Fig 1). By
contrast, a statistically significant decrease (P = 0.0007;
clinical relevance, d = 1.7; CI: 0.9–2.5) of 1.9 RU in
secretion amount was observed in the horses treated
with the experimental treatment (Table 1). A persistent
effect 4 weeks post-treatment was detected in the treat-
ment group with a decrease of 1.5 RU after 4 weeks
(P = 0.0036; clinical relevance, d = 1.5; CI: 0.6–2.2;
Table 1, Fig 1). A statistically significant difference was
detected between placebo and treatment groups when
comparing the percent decrease in quantity of secretion
between the first and the second examinations (I–II;
P = 0.0003) as well as between the first and the third
examinations (I–III; P = 0.0038; Fig 1).
Viscosity of Secretion
No statistically significant decrease in viscosity of the
TBS was observed in the placebo group (Table 1,
Fig 1). However, the treatment group showed a statisti-
cally significant decrease in TBS viscosity of 1.4 RU
(P = 0.0014; clinical relevance, d = 1.3; CI: 0.5–2.1)
after the inhalation regimen (Table 1, Fig 1). A statisti-
cally significant persistent effect was detected in the
treatment group (P = 0.0029; clinical relevance, d = 1.2;
CI: 0.4–1.9; Table 1, Fig 1). A statistically significant
difference was detected between the placebo and treat-
ment groups when comparing percentage decrease in
secretion viscosity between the first and the second
examinations (I–II; P = 0.0014) as well as between the
first and the third examinations (I–III; P = 0.0065;
Fig 1).
Discussion
To the best of our knowledge, this study represents
the first attempt at nanoparticle-based inhalation immu-
notherapy for horses. Clinical examination, endoscopy,
cytology and biochemical variables were evaluated
before treatment to determine the pre-treatment health
status of each horse, as well as immediately after 5
inhalations (10 days after the primary examination),
and 4 weeks after the last treatment to determine the
duration of efficacy. For at least 2 months before and
during the course of the field study, the horses received
no supplement medication or any modifications to their
stabling or management. The patients were treated
under their normal stabling conditions and individual
exposure to allergens.
The method of inhalation was chosen as a local,
topical administration of immunotherapy for the lungs,
and proved to be both practical and appropriate. The
inhalation system used (ie, a combination of “Equine
Haler” and “Aeroneb go”) was already proven in a pre-
vious study26 to be a practical, simple and well-tolerated
system. Its respiratory droplet size,19 quiet nebuliza-
tion,26 and short inhalation time26 proved to be well
adapted for use.
Gelatin nanoparticles have been proven to be immu-
nologically inert, aerodynamically stable, biodegradable,
and well tolerated drug delivery systems. Their particu-
lar relevance lies in their stabilization and protection of
the chimeric backbone26 of the Class A CpG-ODN by
steric shielding, as opposed to DNase;15 in their selec-
tive targeting of the TLR-9 positive target cells; and in
the resulting increased effectiveness of the CpG-
ODN.15,32 These aspects, as well as the fact that GNPs
are used in (potentially) food-producing animals, render
these nanoparticles of a great importance for a potential
application in humans with allergic asthma. The inhala-
tion regimen, with each inhalation session given every
2 days, was selected because of the known maximum
48-hour in vivo stability of the ODN.33
Within the framework of the study design, the pla-
cebo group was intentionally restricted to 8 horses. This
decision was made based on ethical considerations
regarding the animals’ well-being, the expected efficacy
of treatment and the added value of information, as
well as the decrease of animal suffering because of the
severity of the disease. Because of the smaller number
of horses in the placebo group, one cannot expect
exactly identical output values, because of the random
distribution of data. The effect size (Cohen’s d, d > 0.8
for high clinical relevance) and the 95% CI were calcu-
lated in addition to the significance levels, in order to
better assess the clinical relevance of the results pre-
sented in this study.34
To ensure a safe application of the formulation, pos-
sible local and systemic inflammatory reactions or
adverse effects were documented, with the help of a
modified scoring system from the Veterinary Co-opera-
tive oncology Group‘s Common Criteria of Adverse
Events (VCOG-CTCAE) V1.0.35 In accordance with a
previous study, no signs of local or systemic inflamma-
tory reactions (including the measurement of plasma
fibrinogen concentrations and a differential blood
count) or any other adverse effects were observed from
the GNP-bound CpG inhalation treatment. Thus, the
second goal of this field study (verification of treatment
safety) could be completely satisfied.
As it has already been shown in vitro using equine
BAL cells and in vivo, GNP-bound CpG treatment
stimulates upregulation of IL-10.26,32,35 This cytokine,
which among others is formed from Treg cells, has a
regulatory effect on excessive pro-inflammatory Th1
and pro-allergic Th2 immune responses, as they occur
in the lungs of RAO horses to various degrees.8 The
anti-inflammatory and anti-allergic effect of this immu-
notherapy, through the activation of TLR-9 receptors
in the lungs, will, according to our hypothesis, stimulate
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Treg cells to regulate and restore the Th1/Th2 balance
that is disturbed in RAO.
The most important effect of the nanoparticle inhala-
tion immunotherapy was the decrease in secretion quan-
tity (ie, nasal discharge and endoscopic findings) as well
as the auscultation findings, breathing type and the sup-
ply of oxygen to the lungs. Not only was a significant
improvement shown in all of these variables after 5
inhalations but also a sustained effect was documented
after 4 weeks without supplement treatment or modifi-
cations to management conditions. This finding must be
particularly emphasized, because the horses in the study
were not held in optimal conditions and had constant
contact with hay. The clinical relevance of the specific
effects also could be classified as very high (d > 0.8).
Whether the immunotherapy has a particularly pro-
nounced effect on the mucus-producing goblet cells can
only be surmised from these results. In mouse models, it
is clear that Th2-mediated immunopathogenesis can be
modulated and positively influenced by use of immuno-
stimulatory DNA.11,15 The neutrophils, however, showed
a comparatively small decrease, which among other
things could be explained by sustained exposure to aller-
gens. Through repeated inhalations (ie, booster doses), as
was already indicated in our previous pilot study,26,35
and perhaps through a modified dosage (ie, dose-
response study), this effect potentially could be strength-
ened. The previous study also showed an average 30%
increase in reduction of neutrophil granulocytes after 5
inhalations26,35 during the winter treatment, during
which management conditions were optimized.
The improvement of partial oxygen pressure at rest,
as well as intrapleural pressure, indicates improved ven-
tilation in the lungs. This also was reflected in the con-
siderably improved breathing pattern and the decrease
in active respiratory effort. The cause is most likely the
decrease in secretion, as well as a decrease in cholinergic
bronchospasm.
In other studies in which CpGs were deployed, for
example in a study on asthma in humans,20 and a study
on dogs with atopic dermatitis,21 CpGs were used as
adjuvants for an allergen-specific immunotherapy or as
vaccine adjuvants for increased effectiveness of the
human hepatitis B11 and the equine influenza and Rho-
dococcus equi vaccines.22–25 In these studies, the CpGs
induced a strong Th1 cell-mediated and humoral
immune response.11 However, they have never been
deployed previously as an immuno-modulatory mono-
therapy, by inhalation or bound to nanoparticles. As
such, this study represents the first inhalation nanopar-
ticle immunotherapy of its kind and is a novel treat-
ment concept for horses. Its use in allergic asthma in
humans could therefore also be considered.
The advantage of this immunotherapy lies in stimula-
tion independent of allergens, as opposed to classic
hyposensitization. Furthermore, this therapeutic concept
works at the immunologic level and helps stabilize the
Th1/Th2 balance, which can be of clinical relevance for
other allergic and inflammatory diseases. This therapeu-
tic concept opens new possibilities beyond the usual
purely symptomatic treatment concepts with cortisone
and bronchodilators, or the often unfeasible avoidance
of allergen contact. All of the patients included in this
study were kept and examined in their normal manage-
ment conditions, without modifying the usual bedding,
feed (hay), or the use of the horse. The goal was to test
the effectiveness of the inhalative CpG treatment under
individual natural environmental conditions.
The relatively small number of inhalations and the per-
sistent effect over at least a month must be emphasized.
Altogether, a significant improvement was observed in
the treatment group after 5 inhalations, with a persistent
effect over 4 weeks in 70% of the clinical, endoscopic and
cytological variables. Thus, an important goal of the
study, the verification of the clinical efficacy of the con-
cept (Phase IIa), was fulfilled. Upon review of the exam-
inations, the placebo application, as expected, showed no
improvement whatsoever in the variables tested.
Few inhalation treatments have produced a substan-
tial and sustained improvement of allergic and inflam-
matory clinical, endoscopic, cytological, and
biochemical variables. The results of the present field
study completely satisfied the questions posed and fur-
thermore indicated a persistent effect in many of the
variables tested. This therapeutic approach introduces
new perspectives beyond symptomatic treatment meth-
ods, and therefore can serve as a model for asthma
therapy in humans.
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